A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

Conditions

• Cryopyrin Associated Periodic Syndrome

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• VTX2735 — DRUG
  Dose A
• VTX2735 — DRUG
  Dose B

Study Details

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.

Key Dates

Start date

Mar 18, 2023

Status verified

Mar 2025

Primary completion

Mar 6, 2024

Completion

Mar 6, 2024

Study Design

Enrollment

7 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Cohort 1
• Experimental: Cohort 2

Primary Outcome Measure

Safety and Tolerability of VTX2735 [ Time Frame: From the initial administration of VTX2735 through study completion, up to 10 weeks ]

Locations (2)

Find similar trials in San Diego, CA